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Protocol
AbstrAct
Introduction Intra-abdominal infections are the second 
most frequent cause of sepsis. In a recent cohort, 
fungal specimens were found in 51.9% of all patients 
with sepsis and peritonitis. Current systematic reviews 
comparing untargeted antifungal treatment with placebo 
or no treatment in patients who are critically ill have 
provided conflicting results, and clinical equipoise exists. 
Accordingly, we aim to assess patient-important benefits 
and harms of untargeted antifungal therapy versus placebo 
or no treatment in adult patients with complicated intra-
abdominal infection.
Methods and analysis We will conduct a systematic 
review with meta-analysis and trial sequential analysis 
of randomised clinical trials assessing any untargeted 
antifungal therapy compared with placebo or no treatment 
in adult patients with complicated intra-abdominal 
infections. The primary outcome is all-cause mortality, 
and secondary outcomes include adverse events, duration 
of mechanical ventilation and inotropic support, need 
for renal replacement therapy, emergence of antibiotic 
resistance and intensive care unit and hospital length-
of-stay. Conventional meta-analysis, including sensitivity 
and subgroup analyses, and assessment of the risk of 
systematic (bias) and random errors will be conducted. 
The review will be prepared according to the Preferred 
Reporting Items for Systematic Reviews and Meta-
Analyses statement, the Cochrane methodology and the 
Grading of Recommendations, Assessment, Development 
and Evaluation.
Ethics and dissemination Ethical approval is not 
required as this systematic review only includes previously 
published data. We aim to publish the review in an 
international peer-reviewed journal.
Trial registration number International Prospective 
Register of Systematic Reviews registration number: 
CRD42016053508.
Background
description of the condition
Intra-abdominal infections are the second 
most frequent cause of sepsis in critically 
ill patients.1 Complicated intra-abdominal 
infection or peritonitis is characterised by 
inflammation of the peritoneum, most often 
caused by bacteria or fungi. Primary or 
spontaneous bacterial peritonitis occurs due 
to haematogenous dissemination of bacteria 
or translocation of bacteria through the 
enteric wall and is managed without surgical 
intervention.2 Secondary peritonitis is the 
most common form. It develops in relation to 
disease or injury due to breach of the intestinal 
wall and requires immediate source control.2 
Tertiary peritonitis is defined as persistent 
or reoccurring peritonitis within 48 hours 
of adequate surgical source control.2 All 
forms are associated with high morbidity and 
mortality despite administration of relevant 
antibiotics and/or surgical interventions.1–3
In a recent retrospective cohort of criti-
cally ill patients with sepsis due to peritonitis, 
fungal specimens were found in 52% of 
all patients.4 Candida spp constituted the 
majority of isolates, in particular C. albicans 
(60%), C. glabrata (24%) and C. tropicalis 
(9%).4 Patients with fungal infection had a 
significantly higher rate of tertiary peritonitis 
and a higher overall mortality compared with 
patients without fungal infection.4
Strengths and limitations of this study
 ► The protocol has been prepared according to the 
Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses Protocols (PRISMA-P) statement.
 ► The systematic review will be conducted in 
accordance with recommendations from the 
Cochrane Collaboration, the PRISMA statement and 
the Grading of Recommendations, Assessment, 
Development and Evaluation guidelines.
 ► Exclusively patient-important outcome measures, 
including mortality, adverse events, use of life 
support and quality of life, will be evaluated.
 ► The included trials may be heterogeneous.
 ► Different antifungal treatment strategies (ie, 
prophylaxis, pre-emptive and empirical therapy) will 
be assessed.
 ► New as well as older antifungal agents will be 
assessed.
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description of the intervention
Untargeted antifungal treatment is defined as any 
antifungal intervention initiated before definitive micro-
biological evidence of fungi exists.5–8 Currently, three 
different untargeted treatment strategies have been 
defined, namely prophylaxis, pre-emptive and empir-
ical therapy.5–8 Antifungal prophylaxis is used in patients 
with high risk of developing invasive fungal infections, 
including critical illness, recent abdominal surgery, 
haematological malignancy, organ transplantation and 
treatment with glucocorticoids or broad-spectrum antibi-
otics.5–9 Pre-emptive antifungal treatment is administered 
in response to direct or indirect microbiological evidence 
of fungi without clinical suspicion of invasive fungal infec-
tion.5–8 Lastly, empirical antifungal treatment is used in 
patients with known risk factors and suspicion of fungal 
infection.5–8 In daily clinical practice, it is often difficult to 
distinguish the different untargeted antifungal treatment 
strategies.
How the intervention might work
Diagnosing fungal infection is challenging, as symptoms 
and signs are non-specific and mimic bacterial infec-
tions.9 Also, the time to acquire definite diagnosis takes 
several days as it is still largely based on cultures. Thus, 
untargeted therapy strategies appear intuitively attrac-
tive.
In a prospective, population-based surveillance study 
of patients with Candida bloodstream infection, early 
administration of untargeted antifungal treatment was 
associated with reduced mortality.10 11 Similarly, two 
previous systematic reviews investigating prophylactic 
antifungal treatment with fluconazole or ketoconazole 
in non-neutropenic, critically ill patients demonstrated 
a reduction in both invasive fungal infection and 
all-cause mortality compared with placebo or no treat-
ment.12 13 However, in a recently updated Cochrane 
review including a total of 2761 non-neutropenic, 
critically ill adults and children, untargeted anti-
fungal treatment did not significantly reduce mortality 
(moderate quality of evidence). The results did indicate 
a reduction in rates of invasive fungal infections (low 
quality of evidence).5 In conclusion, existing evidence 
have provided conflicting results regarding the use of 
untargeted antifungal therapy.5 12 13
Why it is important to do this review
Several disadvantages of antifungal treatment exist, 
including drug interactions, side effects and economical 
expenses. In addition, resistance is increasing, in partic-
ular to fluconazole, highlighting the need for balancing 
benefits and harms of untargeted antifungal therapy.1 
Existing systematic reviews and meta-analyses on the 
matter are confined to patients who are critically ill. It 
remains to be elucidated if all or certain subgroups of 
adult patients with complicated intra-abdominal infection 
would benefit from treatment with untargeted antifungal 
therapy.
objectives
We aim to assess patient-important benefits and harms of 
untargeted antifungal therapy versus placebo or no treat-
ment in adult patients with complicated intra-abdominal 
infection.
MeTHods
This protocol has been prepared according to the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses Protocols (PRISMA-P) statement.14 Refer to 
online supplementary Appendix for the PRISMA-P check-
list. The systematic review will be conducted in accordance 
with recommendations from the PRISMA statement,15 
and the quality of evidence will be evaluated using the 
Grading of Recommendations, Assessment, Development 
and Evaluation (GRADE) approach.16 This protocol has 
also been registered in the International Prospective 
Register of Systematic Reviews on the 21 December 2016 
(trial registration number CRD42016053508). 
Types of studies
We aim to include randomised clinical trials (RCTs) 
assessing untargeted antifungal therapy in adult patients 
with complicated intra-abdominal infections (as defined 
by the original trials). RCTs regardless of publication 
status, publication period, blinding and language will be 
included. Cross-over trials and quasirandomised trials will 
be excluded.
Types of participants
We will include trials conducted in adult patients (as 
defined by the original trials) with complicated intra-ab-
dominal infection. Trials conducted in neutropenic as 
well as non-neutropenic patients  will be included. RCTs 
conducted in animals, children and healthy subjects will 
be excluded.
Types of interventions
The interventions of interest include any type of 
untargeted antifungal therapy, including azoles, echino-
candins, polyenes, allylamines and nucleoside analogues 
in any dose, timing, formulation and duration. Trials are 
permitted to have more than one intervention group. 
The comparators are patients receiving either placebo or 
no treatment.
Types of outcome measures
Exclusively patient-important outcome measures will be 
evaluated.17 The primary outcome measure is all-cause 
short-term mortality (≤90 days, including in-ICU (inten-
sive care unit) and in-hospital mortality). Secondary 
outcomes include (1) long-term mortality (>90 days), 
(2) adverse events (as defined by the original trials) at 
longest follow-up, (3) duration of mechanical ventila-
tion, (4) days free of mechanical ventilation, (5) need for 
renal replacement therapy at longest follow-up, (6) days 
free of renal replacement therapy, (7) duration of vaso-
pressor/inotropic support, (8) days free of vasopressors/
group.bmj.com on February 26, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
 3Petersen MW, et al. BMJ Open 2017;7:e015900. doi:10.1136/bmjopen-2017-015900
Open Access
inotropes, (9) emergence of antibiotic resistance at 
longest follow-up, (10) emergence of fungi not suscep-
tible to given antifungal agent, (11) ICU length-of-stay 
(LOS), (12) hospital LOS and (13) quality of life (as 
defined by the original trials) at longest follow-up. If 
multiple time points are reported, we will use and report 
the outcome with longest follow-up.
search methods for identification of studies
Electronic searches
We will systematically search the Cochrane Library (Wiley 
interface, current issue), Medline (OVID interface, 1946 
onwards), Embase (OVID interface, 1980 onwards) and 
Epistemonikos. Refer to online supplementary Appendix 
for example of full search strategy performed in Medline.
Searching other resources
Additionally, we will hand-search reference lists of rele-
vant trials and other systematic reviews of untargeted 
antifungal therapy. Unpublished trials will be sought 
identified by performing an equivalent search strategy in 
other registers (eg,  ClinicalTrials. gov, European Clinical 
Trials Database).
data collection and analysis
Selection of studies
Two independent authors will screen titles and abstracts 
of identified trials. Relevant trials will be evaluated in 
full text for eligibility. Disagreements will be resolved 
by discussion between authors and finally by consensus 
among all authors.
data extraction and management
Two independent authors will extract data from included 
trials in duplicate using a standardised data extraction 
form. Data items abstracted will include trial characteris-
tics, patient characteristics, details of intervention(s) and 
comparator(s), risk of bias and the predefined patient-im-
portant outcome measures. We aim to include data from 
intention-to-treat analysis rather than per protocol. 
Disagreements will be resolved by discussion between 
data extracting authors and finally by consensus among 
all authors.
Measures of treatment effect
Dichotomous data will be analysed by calculating the 
cumulative relative risk (RR) with 95% confidence 
interval (CI). For continuous data, we will calculate the 
mean difference with corresponding standard deviation 
(SD).
assessment of risk of bias in included studies
Two authors will independently assess risk of bias of the 
included trials in accordance with the recommenda-
tions from the Cochrane Collaboration.18 The domains 
reviewed include (1) random sequence generation, (2) 
allocation concealment, (3) blinding of participants and 
personnel, (4) blinding of outcome assessors, (5) incom-
plete outcome data, (6) selective outcome reporting and 
(7) other bias, including baseline imbalance, early stop-
ping, bias due to vested financial interest and academic 
bias. If one or more domains are judged as being high or 
unclear, we will classify the trial as having an overall high 
risk of bias.
assessment of the risk of random errors
The risk of random errors will be assessed by trial sequen-
tial analysis (TSA).19 TSA is a sample size calculation 
(interim analysis) for meta-analyses that widens the CIs in 
case data are too sparse to draw firm conclusions.19
We will apply trial sequential monitoring boundaries 
according to an information size suggested by the trials 
with low risk of bias and an a priori 20% RR reduction, 
alpha 5%, beta 90% and a control event proportion as 
per the control arm.19
dealing with missing data
Authors will be contacted for additional data if relevant.
assessment of heterogeneity
We will calculate inconsistency factor (I2) and diversity 
factor (D2) to quantify heterogeneity among included 
trials. We will use both fixed effects and random effects 
modelling and report the most conservative estimate.
assessment of small trial bias
We will assess the risk of small trial bias (publication bias) 
if 10 or more trials are included by visually examining the 
funnel plots for asymmetry.20
data synthesis
Review Manager (RevMan V.5.3) will be used as statis-
tical software to conduct the meta-analyses, including 
subgroup analyses (summary estimates). For the TSAs 
we will use the TSA software available from Copenhagen 
Trial Unit, Denmark.
subgroup analysis
We will perform the following subgroup analyses by 
comparing estimates of the pooled intervention effect in 
each subgroup, if two of more trials exist:
 ► Overall low risk of bias versus overall high risk of 
bias. Hypothesised direction of subgroup effect: 
increased intervention effect in trials with high risk 
of bias.
 ► Prophylactic versus pre-emptive versus empirical 
treatment strategies. Hypothesised direction of 
subgroup effect: increased intervention effect in 
trials assessing empirical antifungal treatment.
 ► Non-ICU trials versus ICU trials. Hypothesised 
direction of subgroup effect: increased intervention 
effect in trials conducted in the ICU.
 ► Trials published before the year 2000 versus in 
and after the year 2000. Hypothesised direction of 
subgroup: increased intervention effect in trials 
published before the year 2000.
 ► Patients with primary versus secondary versus 
tertiary peritonitis. Hypothesised direction of 
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subgroup effect: increased intervention effect in 
trials conducted in patients with tertiary peritonitis.
 ► Patients with versus without septic shock. 
Hypothesised direction of subgroup effect: increased 
intervention effect in trials conducted in patients 
with septic shock.
 ► Median/mean Mannheim Peritonitis Index (MPI) 
score >25 versus trials with a median/mean baseline 
MPI score ≤25. Hypothesised direction of subgroup 
effect: increased intervention effect in trials 
conducted on patients with a MPI score >25.
 ► Patients with neutropenia versus patients without 
neutropenia. Hypothesised direction of subgroup 
effect: increased intervention effect in trials 
conducted in patients who are neutropenic.
We will use χ2 test to assess statistical heterogeneity 
between studies (test of interaction) with a p value of 0.10 
considered statistically significant.
sensitivity analysis
In the zero event trials, empirical continuity correction 
will be applied.21
summary of findings
The quality of evidence for each outcome will be assessed 
according to GRADE.16The domains assessed include 
risk of bias, inconsistency, indirectness, imprecision and 
publication bias.16 
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